KNSA
$47.02
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokin...
Recent News
KalVista Pharmaceuticals Stock Sees RS Rating Jump To 86
The Relative Strength (RS) Rating for KalVista Pharmaceuticals stock entered a new percentile Wednesday, with a rise from 79 to 86. Decades of market research shows that the best-performing stocks typically have an 80 or higher RS Rating as they begin their biggest price moves. Is KalVista Pharmaceuticals Stock A Buy?
Viking Therapeutics Stock Gets RS Rating Upgrade
Viking Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating
Xenon Pharmaceuticals Stock Sees RS Rating Rise To 77
Xenon Pharmaceuticals shows improving price performance, earning an upgrade to its IBD Relative Strength Rating
Assessing Kiniksa Pharmaceuticals (KNSA) Valuation After Recent Share Price Volatility
Kiniksa Pharmaceuticals International (KNSA) has drawn investor interest after a period in which the share price increased roughly 1.7% in the past day but declined about 9% over the past week. See our latest analysis for Kiniksa Pharmaceuticals International. That mix of a 1.71% 1 day share price return and a 7 day share price return of 8.96% suggests short term momentum has cooled, even as the year to date share price return of 3.54% and a very large 1 year total shareholder return hint at...
Kiniksa price target raised to $53 from $50 at Wedbush
Wedbush analyst David Nierengarten raised the firm’s price target on Kiniksa (KNSA) to $53 from $50 and keeps an Outperform rating on the shares. The firm notes Arcalyst net product revenue of $202.1M in Q4 and $677.6M for FY25 was in line with the pre-announcement and exceeded its prior estimates, reflecting continued expansion in prescriber breadth and depth alongside longer duration of therapy.Claim 70% Off TipRanks PremiumUnlock hedge fund-level data and powerful investing tools for smarter,